Your browser is no longer supported. Please, upgrade your browser.
Settings
UTHR United Therapeutics Corporation daily Stock Chart
UTHR [NASD]
United Therapeutics Corporation
Index- P/E8.62 EPS (ttm)14.22 Insider Own0.10% Shs Outstand44.89M Perf Week-0.40%
Market Cap5.50B Forward P/E11.12 EPS next Y11.03 Insider Trans-46.52% Shs Float44.35M Perf Month1.31%
Income656.80M PEG- EPS next Q3.64 Inst Own94.00% Short Float14.13% Perf Quarter-27.01%
Sales1.60B P/S3.44 EPS this Y19.90% Inst Trans0.80% Short Ratio9.62 Perf Half Y-8.19%
Book/sh46.66 P/B2.63 EPS next Y-23.55% ROA28.10% Target Price122.58 Perf Year7.88%
Cash/sh25.76 P/C4.76 EPS next 5Y- ROE34.50% 52W Range97.52 - 169.89 Perf YTD-14.54%
Dividend- P/FCF7.87 EPS past 5Y33.00% ROI38.40% 52W High-27.85% Beta1.57
Dividend %- Quick Ratio3.30 Sales past 5Y16.60% Gross Margin94.60% 52W Low25.69% ATR2.66
Employees750 Current Ratio3.50 Sales Q/Q0.40% Oper. Margin60.10% RSI (14)43.75 Volatility1.87% 2.56%
OptionableYes Debt/Eq0.00 EPS Q/Q-19.50% Profit Margin41.00% Rel Volume0.58 Prev Close121.64
ShortableYes LT Debt/Eq0.00 EarningsApr 26 BMO Payout0.00% Avg Volume651.37K Price122.57
Recom3.20 SMA200.15% SMA50-4.54% SMA200-8.08% Volume375,132 Change0.76%
Apr-27-17Reiterated Wedbush Outperform $229 → $213
Mar-30-17Initiated UBS Sell $112
Mar-16-17Initiated Credit Suisse Underperform
Mar-06-17Downgrade Jefferies Hold → Underperform
Feb-23-17Downgrade Ladenburg Thalmann Buy → Neutral
Jan-19-17Downgrade Standpoint Research Buy → Hold
Dec-15-16Initiated Oppenheimer Outperform
Oct-28-16Upgrade Ladenburg Thalmann Neutral → Buy
Jun-15-16Downgrade H.C. Wainwright Buy → Neutral $175 → $95
Apr-29-16Downgrade Ladenburg Thalmann Buy → Neutral
Apr-11-16Reiterated RBC Capital Mkts Sector Perform $150 → $122
Mar-28-16Reiterated Wedbush Outperform $238 → $229
Mar-02-16Reiterated Wedbush Outperform $244 → $238
Feb-10-16Upgrade Standpoint Research Hold → Buy $148
Jul-31-15Reiterated Argus Buy $205 → $200
Jul-29-15Reiterated RBC Capital Mkts Sector Perform $160 → $175
May-27-15Reiterated Argus Buy $195 → $205
Apr-29-15Reiterated RBC Capital Mkts Sector Perform $135 → $160
Mar-12-15Upgrade Argus Hold → Buy $195
Mar-04-15Downgrade Standpoint Research Buy → Hold
May-19-17 06:50AM  United Therapeutics reworks deal ahead of a key patent's expiration American City Business Journals
May-16-17 08:15AM  Blog Coverage: Ionis Pharma Reported Positive Phase III Results in Patients with Familial Amyloid Polyneuropathy Accesswire
May-15-17 04:50PM  ETFs with exposure to United Therapeutics Corp. : May 15, 2017 Capital Cube
May-12-17 08:30AM  SteadyMed Reports First Quarter 2017 Financial Results and Provides Corporate Update GlobeNewswire
May-02-17 04:48PM  ETFs with exposure to United Therapeutics Corp. : May 2, 2017 Capital Cube
May-01-17 10:27AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q1, 2017 By the Numbers : May 1, 2017 Capital Cube
10:02AM  United Therapeutics' Martine Rothblatt saw pay jump last year amid executive shakeup American City Business Journals
Apr-28-17 11:51AM  United Therapeutics partners with 3-D printer to make human organs American City Business Journals
08:00AM  Edited Transcript of UTHR earnings conference call or presentation 26-Apr-17 1:00pm GMT Thomson Reuters StreetEvents
Apr-27-17 08:00PM  United Therapeutics Announces $250 Million Share Repurchase Program PR Newswire
11:29AM  United Therapeutics (UTHR) Q1 Earnings Beat, Sales Miss Zacks
08:15AM  Blog Coverage3D Systems and United Therapeutics Partner to Develop 3D Bioprinted Lungs Accesswire
Apr-26-17 03:39PM  These Greater Washington companies may be most affected by Trump's tax reform American City Business Journals
12:32PM  3D Systems signs 'bioprinting' agreement to eventually create human organs American City Business Journals
06:10AM  United Therapeutics beats 1Q profit forecasts Associated Press
06:00AM  United Therapeutics Corporation Reports First Quarter 2017 Financial Results PR Newswire
06:00AM  3D Systems and United Therapeutics Announce Bioprinting Agreement PR Newswire
Apr-25-17 06:50AM  Drug Stocks Q1 Earnings Releases on Apr 26: AMGN, GSK & More Zacks
Apr-19-17 03:58PM  Rising Revenue and Earnings: Mistubishi Financial, United Therapeutics GuruFocus.com
06:00AM  United Therapeutics Corporation To Report First Quarter 2017 Financial Results Before The Market Opens On Wednesday, April 26, 2017 PR Newswire
Apr-18-17 08:30AM  PolarityTE(TM), Inc. Recruits Key Additions to Management Marketwired
Apr-17-17 01:03PM  5 Major Drug Stocks Likely to Beat Q1 Earnings Estimates Zacks
Apr-04-17 10:31AM  Company News for April 04, 2017 Zacks
10:31AM  Company News for April 04, 2017
07:02AM  United Therapeutics Tanks, Remodulin Pump Launch Delayed Zacks
07:02AM  United Therapeutics Tanks, Remodulin Pump Launch Delayed
Apr-03-17 04:52PM  Why DryShips, United Therapeutics, and Fiat Chrysler Automobiles Slumped Today Motley Fool -8.44%
04:52PM  Why DryShips, United Therapeutics, and Fiat Chrysler Automobiles Slumped Today at Motley Fool
11:55AM  SteadyMed Wins Patent Challenge Vs United Therapeutics Investopedia
11:55AM  SteadyMed Wins Patent Challenge Vs United Therapeutics at Investopedia
10:08AM  United Therapeutics shares fall after regulatory delays push back product launch CNBC
10:08AM  United Therapeutics shares fall after regulatory delays push back product launch at CNBC
10:07AM  United Therapeutics loses challenge to its drug patent at bizjournals.com
10:07AM  United Therapeutics loses challenge to its drug patent American City Business Journals
09:42AM  Stocks Open Higher; United Therapeutics Dives Investor's Business Daily
09:42AM  Stocks Open Higher; United Therapeutics Dives
09:29AM  Biotech Movers: Novocure, United Therapeutics, Kite Pharma TheStreet.com
09:29AM  Biotech Movers: Novocure, United Therapeutics, Kite Pharma
08:00AM  Cardiome's Partner SteadyMed Receives Favourable Ruling in its USPTO Inter Partes Review CNW Group
06:56AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure
06:00AM  United Therapeutics Announces Regulatory Delays For Remosynch Implantable Pump PR Newswire
Mar-31-17 01:40PM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Regulation FD Disclosure
01:15PM  United Therapeutics Announces Decision From Patent Trial And Appeal Board And Issuance Of New Patents PR Newswire
Mar-30-17 09:24AM  Coverage initiated on United Therapeutics by UBS
Mar-28-17 02:43AM  Why Is United Therapeutics (UTHR) Down 5.6% Since the Last Earnings Report?
Mar-21-17 10:05AM  Is United Therapeutics a Great Stock for Value Investors?
Mar-20-17 07:25AM  How These Drug Makers Stocks are Faring? -- Orexigen Therapeutics, United Therapeutics, DURECT, and SciClone Pharma PR Newswire
Mar-17-17 11:03AM  3 Drug Stocks With Some of the Highest Profit Margins at Motley Fool
Mar-16-17 02:01PM  United Therapeutics Stock Slumping on Credit Suisse Rating
Mar-09-17 06:00AM  Northwell Health and United Therapeutics Announce Strategic Partnership to Advance Bioelectronic Medicine and Cell Therapy PR Newswire
Mar-07-17 06:00AM  United Therapeutics Corporation To Present At Barclays Global Healthcare Conference PR Newswire
Feb-28-17 10:36AM  Will Alexions Research Make Gains in the Inhibitor Space?
09:09AM  Alnylam Pharmaceuticals Advances Its Patisiran Research Program
06:00AM  United Therapeutics Corporation To Present At Cowen And Company 37th Annual Health Care Conference PR Newswire
Feb-25-17 01:04PM  UNITED THERAPEUTICS CORP Financials
Feb-24-17 02:06PM  Vertex Expects Modest Revenue Growth in This
Feb-23-17 05:39PM  United Therapeutics feels squeeze from increased pulmonary hypertension competition at bizjournals.com
11:36AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: 2016 By the Numbers : February 23, 2017
09:18AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q4, 2016 By the Numbers : February 23, 2017
09:03AM  United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss
Feb-22-17 05:08PM  Better Buy: Organovo Holdings, Inc. vs. United Therapeutics Corporation at Motley Fool -12.47%
09:00AM  United Therapeutics Corp Earnings Call scheduled for 9:00 am ET today
06:43AM  United Therapeutics beats 4Q profit forecasts
06:09AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Results of Operations and Financial Condition
06:08AM  UNITED THERAPEUTICS CORP Files SEC form 10-K, Annual Report
06:00AM  United Therapeutics Corporation Reports 2016 Fourth Quarter And Annual Financial Results PR Newswire
Feb-15-17 06:00AM  United Therapeutics Corporation To Report Fourth Quarter And Annual 2016 Financial Results Before The Market Opens On Wednesday, February 22, 2017 PR Newswire
Feb-07-17 02:39PM  Your Guide To 2017's Emerging Pharmaceuticals Catalysts
Feb-03-17 06:27AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
Jan-30-17 06:06AM  UNITED THERAPEUTICS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financi
Jan-11-17 11:10PM  D.C.-area biotech stocks fall on Trump's tough talk on industry at bizjournals.com -6.35%
03:24PM  VIVUS Licenses Rights to PAH Drugs from Selten Pharma
Jan-05-17 08:27AM  New Strong Buy Stocks for January 5th
06:00AM  United Therapeutics Corporation To Present At 35th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-29-16 01:14PM  Vertex Pharmaceuticals Expects Strong Revenue Growth in 2016
10:10AM  United Therapeutics' PAH Suite Bodes Well, Competition Rife
09:06AM  United Therapeutics: Will RemoSynch Become a Key Growth Driver?
07:36AM  United Therapeutics Robust Research Pipeline
Dec-28-16 02:05PM  United Therapeutics: Will Orenitram See Strong Patient Demand?
12:35PM  United Therapeutics: Why Tyvaso Is Still a Key Growth Driver
10:55AM  Why United Therapeutics Expects Strong Revenue Growth
Dec-16-16 10:35AM  Dupixent Is Being Explored for Multiple Indications in 2016
Dec-12-16 04:21PM  The 3 Most Profit-Friendly Biotech Stocks at Motley Fool +5.51%
Dec-07-16 05:07PM  Are there buying opportunities in health care?
Dec-02-16 08:05AM  NBIX Continues to Study Valbenazine for Tourette Syndrome
04:29AM  Hedge Funds Are Selling Patterson Companies, Inc. (PDCO) at Insider Monkey
Dec-01-16 02:25PM  Pig organs to save lives by end of decade: United Therape...
11:32AM  Hedge Funds Are Buying WellCare Health Plans, Inc. (WCG) at Insider Monkey
Nov-30-16 11:17AM  What Happens When Your Biotech Stock Faces Generic Competition Lawsuits? at Motley Fool
Nov-25-16 08:32AM  J&J (JNJ) Reportedly Approaches Actelion for Acquisition
Nov-21-16 01:19PM  5 Most Expensive Medicare Drugs -- and Which Companies Are Getting Rich From Them at Motley Fool
Nov-09-16 04:29PM  How Greater Washington stocks fared post-election at bizjournals.com +7.16%
07:27AM  United Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : November 9, 2016
Nov-08-16 05:35PM  Palo Alto Investorss Bets on ABIOMED, Inc. (ABMD), United Therapeutics Corporation (UTHR) and Other Stocks Lift Its Q3 Returns at Insider Monkey
Nov-04-16 01:17AM  Mallinckrodt PLC (MNK) & Depomed Inc (DEPO) Helped Consonance Capital to Massive Q3 Returns at Insider Monkey
Nov-01-16 05:54PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating United Therapeutics Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors Accesswire
Oct-31-16 05:50PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Breaches of Fiduciary Duty by the Board of United Therapeutics Corporation -- UTHR Accesswire
01:06PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating United Therapeutics Corporation for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
10:39AM  United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q3, 2016 By the Numbers : October 31, 2016
Oct-28-16 09:58AM  United Therapeutics (UTHR) Beats Q3 Earnings, Sales Miss
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy. In addition, the company develops RemoSynch and RemUnity delivery systems for intravenous and subcutaneous Remodulin; esuberaprost and eNOS gene therapies for PAH; and organ transplantation-related technologies, including regenerative medicines, xenotransplantation, and ex-vivo lung perfusion. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROTHBLATT MARTINE AChairman & CEOMay 18Option Exercise30.751,26138,7761,401May 22 09:27 AM
ROTHBLATT MARTINE AChairman & CEOMay 18Option Exercise30.7591528,136657,529May 22 09:27 AM
MAHON PAUL AEVP & General CounselMay 18Option Exercise51.376,000308,22041,426May 22 09:29 AM
ROTHBLATT MARTINE AChairman & CEOMay 18Sale120.721,261152,225140May 22 09:27 AM
ROTHBLATT MARTINE AChairman & CEOMay 11Option Exercise30.751,25938,7141,399May 15 09:32 AM
ROTHBLATT MARTINE AChairman & CEOMay 11Option Exercise30.7591828,229656,614May 15 09:32 AM
ROTHBLATT MARTINE AChairman & CEOMay 11Sale122.001,259153,599140May 15 09:32 AM
MAHON PAUL AEVP & General CounselMay 04Option Exercise51.376,000308,22041,426May 05 04:07 PM
ROTHBLATT MARTINE AChairman & CEOMay 04Option Exercise30.751,25838,6841,398May 05 04:09 PM
ROTHBLATT MARTINE AChairman & CEOMay 04Option Exercise30.7591828,229655,696May 05 04:09 PM
CAUSEY CHRISTOPHERDirectorMay 04Option Exercise53.571,25066,9631,725May 05 04:08 PM
ROTHBLATT MARTINE AChairman & CEOMay 04Sale122.241,258153,774140May 05 04:09 PM
ROTHBLATT MARTINE AChairman & CEOApr 27Option Exercise30.751,26238,8071,402Apr 28 04:03 PM
ROTHBLATT MARTINE AChairman & CEOApr 27Option Exercise30.7591528,136654,778Apr 28 04:03 PM
ROTHBLATT MARTINE AChairman & CEOApr 27Sale120.781,262152,422140Apr 28 04:03 PM
MAHON PAUL AEVP & General CounselApr 20Option Exercise51.376,000308,22041,426Apr 21 05:50 PM
ROTHBLATT MARTINE AChairman & CEOApr 20Option Exercise30.751,26038,7451,400Apr 21 05:51 PM
ROTHBLATT MARTINE AChairman & CEOApr 20Option Exercise30.7591628,167653,863Apr 21 05:51 PM
ROTHBLATT MARTINE AChairman & CEOApr 20Sale121.141,260152,633140Apr 21 05:51 PM
ROTHBLATT MARTINE AChairman & CEOApr 13Option Exercise30.751,25838,6841,398Apr 14 04:08 PM
ROTHBLATT MARTINE AChairman & CEOApr 13Option Exercise30.7591928,259652,947Apr 14 04:08 PM
ROTHBLATT MARTINE AChairman & CEOApr 13Sale122.121,258153,625140Apr 14 04:08 PM
CAUSEY CHRISTOPHERDirectorApr 06Option Exercise53.571,25066,9631,725Apr 10 04:13 PM
MAHON PAUL AEVP & General CounselApr 06Option Exercise51.376,000308,22041,426Apr 10 04:17 PM
ROTHBLATT MARTINE AChairman & CEOApr 06Option Exercise30.751,25738,6531,397Apr 10 04:18 PM
ROTHBLATT MARTINE AChairman & CEOApr 06Option Exercise30.7591928,259652,028Apr 10 04:18 PM
ROTHBLATT MARTINE AChairman & CEOApr 06Sale122.391,257153,848140Apr 10 04:18 PM
ROTHBLATT MARTINE AChairman & CEOMar 30Option Exercise30.751,23037,8231,370Mar 31 04:02 PM
ROTHBLATT MARTINE AChairman & CEOMar 30Option Exercise30.7594729,120651,109Mar 31 04:02 PM
ROTHBLATT MARTINE AChairman & CEOMar 30Sale134.561,230165,509140Mar 31 04:02 PM
ROTHBLATT MARTINE AChairman & CEOMar 23Option Exercise30.751,21937,4841,359Mar 27 04:14 PM
ROTHBLATT MARTINE AChairman & CEOMar 23Option Exercise30.7595729,428650,162Mar 27 04:14 PM
ROTHBLATT MARTINE AChairman & CEOMar 23Sale139.331,219169,842140Mar 27 04:14 PM
Thompson Tommy GDirectorMar 22Option Exercise54.772,000109,5402,000Mar 23 04:26 PM
Thompson Tommy GDirectorMar 22Sale139.372,000278,7400Mar 23 04:26 PM
ROTHBLATT MARTINE AChairman & CEOMar 16Option Exercise30.751,21837,4541,358Mar 20 04:44 PM
ROTHBLATT MARTINE AChairman & CEOMar 16Option Exercise30.7595929,489649,205Mar 20 04:44 PM
MAHON PAUL AEVP & General CounselMar 16Option Exercise51.376,000308,22041,426Mar 20 04:45 PM
ROTHBLATT MARTINE AChairman & CEOMar 16Sale140.161,218170,709140Mar 20 04:44 PM
ROTHBLATT MARTINE AChairman & CEOMar 09Option Exercise30.751,20637,0851,346Mar 13 09:24 AM
ROTHBLATT MARTINE AChairman & CEOMar 09Option Exercise30.7597029,828648,246Mar 13 09:24 AM
PATUSKY CHRISTOPHERDirectorMar 09Option Exercise48.113,000144,3303,000Mar 13 09:25 AM
ROTHBLATT MARTINE AChairman & CEOMar 09Sale146.721,206176,949140Mar 13 09:24 AM
ROTHBLATT MARTINE AChairman & CEOMar 02Option Exercise30.751,20336,9921,343Mar 03 05:02 PM
ROTHBLATT MARTINE AChairman & CEOMar 02Option Exercise30.7597429,951647,276Mar 03 05:02 PM
MAHON PAUL AEVP & General CounselMar 02Option Exercise51.376,000308,22041,221Mar 03 05:03 PM
CAUSEY CHRISTOPHERDirectorMar 02Option Exercise53.571,25066,9631,725Mar 03 05:07 PM
ROTHBLATT MARTINE AChairman & CEOMar 02Sale148.491,203178,632140Mar 03 05:02 PM
ROTHBLATT MARTINE AChairman & CEOFeb 23Option Exercise30.751,20837,1461,348Feb 24 04:03 PM
ROTHBLATT MARTINE AChairman & CEOFeb 23Option Exercise30.7596829,766646,302Feb 24 04:03 PM
ROTHBLATT MARTINE AChairman & CEOFeb 23Sale145.161,208175,356140Feb 24 04:03 PM
ROTHBLATT MARTINE AChairman & CEOFeb 16Option Exercise30.751,17336,0701,313Feb 17 04:54 PM
ROTHBLATT MARTINE AChairman & CEOFeb 16Option Exercise30.751,00430,873645,334Feb 17 04:54 PM
MAHON PAUL AEVP & General CounselFeb 16Option Exercise51.376,000308,22041,221Feb 17 04:55 PM
ROTHBLATT MARTINE AChairman & CEOFeb 16Sale167.921,173196,966140Feb 17 04:54 PM
ROTHBLATT MARTINE AChairman & CEOFeb 09Option Exercise30.751,17836,2241,318Feb 13 05:21 PM
ROTHBLATT MARTINE AChairman & CEOFeb 09Option Exercise30.7599830,689644,330Feb 13 05:21 PM
CAUSEY CHRISTOPHERDirectorFeb 02Option Exercise53.571,25066,9632,225Feb 03 04:14 PM
ROTHBLATT MARTINE AChairman & CEOFeb 02Option Exercise30.751,18136,3161,321Feb 03 04:17 PM
ROTHBLATT MARTINE AChairman & CEOFeb 02Option Exercise30.7599630,627643,332Feb 03 04:17 PM
MAHON PAUL AEVP & General CounselFeb 02Option Exercise51.376,000308,22041,221Feb 03 04:16 PM
ROTHBLATT MARTINE AChairman & CEOJan 26Option Exercise30.751,18636,4701,326Jan 27 05:29 PM
ROTHBLATT MARTINE AChairman & CEOJan 26Option Exercise30.7599030,443642,336Jan 27 05:29 PM
ROTHBLATT MARTINE AChairman & CEOJan 19Option Exercise30.751,19536,7461,335Jan 20 05:21 PM
ROTHBLATT MARTINE AChairman & CEOJan 19Option Exercise30.7598230,197641,346Jan 20 05:21 PM
MAHON PAUL AEVP & General CounselJan 19Option Exercise54.806,000328,78039,221Jan 23 04:12 PM
ROTHBLATT MARTINE AChairman & CEOJan 12Option Exercise30.751,21437,3311,354Jan 12 04:30 PM
ROTHBLATT MARTINE AChairman & CEOJan 12Option Exercise30.7596229,582640,364Jan 12 04:30 PM
PATUSKY CHRISTOPHERDirectorJan 12Option Exercise30.755,000153,7505,000Jan 12 04:32 PM
ROTHBLATT MARTINE AChairman & CEOJan 12Sale142.371,214172,840140Jan 12 04:30 PM
PATUSKY CHRISTOPHERDirectorJan 12Sale141.995,000709,9690Jan 12 04:32 PM
MAHON PAUL AEVP & General CounselJan 05Option Exercise50.096,000300,54041,221Jan 06 04:05 PM
CAUSEY CHRISTOPHERDirectorJan 05Option Exercise53.571,25066,9631,715Jan 06 04:06 PM
ROTHBLATT MARTINE AChairman & CEOJan 05Option Exercise30.751,20837,1461,348Jan 06 04:08 PM
ROTHBLATT MARTINE AChairman & CEOJan 05Option Exercise30.7596929,797639,402Jan 06 04:08 PM
ROTHBLATT MARTINE AChairman & CEOJan 05Sale145.731,208176,044140Jan 06 04:08 PM
ROTHBLATT MARTINE AChairman & CEODec 29Option Exercise30.751,21137,2381,351Jan 03 04:09 PM
ROTHBLATT MARTINE AChairman & CEODec 29Option Exercise30.7596529,674638,433Jan 03 04:09 PM
ROTHBLATT MARTINE AChairman & CEODec 29Sale143.631,211173,940140Jan 03 04:09 PM
ROTHBLATT MARTINE AChairman & CEODec 22Option Exercise30.751,21837,4541,358Dec 23 11:39 AM
ROTHBLATT MARTINE AChairman & CEODec 22Option Exercise30.7595929,489637,468Dec 23 11:39 AM
ROTHBLATT MARTINE AChairman & CEODec 22Sale140.231,218170,800140Dec 23 11:39 AM
MAHON PAUL AEVP & General CounselDec 15Option Exercise50.096,000300,54041,221Dec 16 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 15Option Exercise30.751,21237,2691,352Dec 16 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 15Option Exercise30.7596429,643636,509Dec 16 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 15Sale143.111,212173,446140Dec 16 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 08Option Exercise30.751,23638,0071,376Dec 09 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 08Option Exercise30.7594128,936650,528Dec 09 04:05 PM
ROTHBLATT MARTINE AChairman & CEODec 08Sale131.781,236162,875140Dec 09 04:05 PM
Giltner RichardDirectorDec 06Option Exercise41.145,000205,7005,000Dec 07 04:20 PM
Giltner RichardDirectorDec 06Sale133.375,000666,8450Dec 07 04:20 PM
CAUSEY CHRISTOPHERDirectorDec 01Option Exercise51.771,25064,7131,855Dec 02 04:15 PM
ROTHBLATT MARTINE AChairman & CEODec 01Option Exercise30.751,24638,3151,386Dec 02 04:20 PM
ROTHBLATT MARTINE AChairman & CEODec 01Option Exercise30.7593028,598649,587Dec 02 04:20 PM
MAHON PAUL AEVP & General CounselDec 01Option Exercise50.096,000300,54041,221Dec 02 04:19 PM
ROTHBLATT MARTINE AChairman & CEODec 01Sale126.861,246158,063140Dec 02 04:20 PM
ROTHBLATT MARTINE AChairman & CEONov 25Option Exercise30.751,23337,9151,373Nov 29 04:07 PM
ROTHBLATT MARTINE AChairman & CEONov 25Option Exercise30.7594429,028648,657Nov 29 04:07 PM
ROTHBLATT MARTINE AChairman & CEONov 25Sale132.811,233163,749140Nov 29 04:07 PM
MAHON PAUL AEVP & General CounselNov 17Option Exercise50.096,000300,54041,221Nov 21 04:09 PM